Shots:

• The study is sponsored by Tempus, entitled “Niraparib in the Treatment of Patients with Advanced PALB2 Mutated Tumors” (the PAVO study), and opened for enrollment on Jan 07, 2022
• The PAVO study will enroll solid tumor patients with germline or somatic PALB2 mutations. Tempus is utilizing its TIME Trial Program to support rapid patient identification, site activation, and clinical trial enrollment
• Zejula is a PARP inhibitor that was approved by the US FDA in 2017 for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer

Ref: Tempus | Image: GSK